This content is machine translated Continuing education series on type 2 diabetes (2021) Dia-Month Club Module 2: (Post-)Pandemic On May 17, the second module of the Dia-Month Club on the (post)pandemic took place. Our expert, Prof. Marc Donath (University Hospital Basel), spoke on the exciting question: Does Covid-19… CME-Test
View Post 1 min This content is machine translated Continuing education series on type 2 diabetes (2021) Dia-Month Club Module 3: LDL cholesterol On June 25, the third module of the Dia-Month Club took place, focusing on an often underestimated risk factor, LDL cholesterol. Our expert, Prof. Isabella Sudano (University Hospital Zurich), presented… CME-Test
View Post 1 min This content is machine translated Continuing education series on type 2 diabetes (2021) Dia-Month Club Module 4: Heart In the fourth module of the Dia-Month Club on September 3, Prof. Christian Müller (University Hospital Basel) used current data to show how modern diabetes management decisively reduces the patient’s… CME-Test
View Post 1 min This content is machine translated Continuing education series on type 2 diabetes (2021) Dia-Month Club Module 5: Kidney On October 26, the fifth module of the Dia-Month Club was held on the topic of kidneys. Our expert, PD Dr. Michael Mayr (University Hospital Basel), explained the practical guardrails… CME-Test
View Post 1 min This content is machine translated Continuing education series on type 2 diabetes (2021) Dia-Month Club Module 6: Consequential diseases On November 18, the sixth module of the Dia-Month Club was held on the topic of secondary diseases of type 2 diabetes. Our expert, Dr. Thanh-Truc Ngô Bá (St. Claraspital,… CME-Test
View Post 1 min This content is machine translated Continuing education series on type 2 diabetes (2021) Dia-Month Club Module 7: Digital Tools On December 9, the seventh and final module of the 2021 Dia-Month Club was held on the topic of digital tools. Our expert, Prof. Roger Lehmann (University Hospital Zurich), explained… CME-Test
View Post 4 min This content is machine translated Practice Check Ozanimod in clinical routine Following approval of the new active ingredient in Switzerland, its use in practice is now being investigated. An important practical aspect of the drug is the oral route of administration.…
View Post 4 min This content is machine translated Tolerability Check On the downside: throat and liver In terms of tolerability, ozanimod compares favorably with other sphingosine-1-phosphate receptor modulators [1–3]*. In the pivotal studies, drop-out rates due to adverse events were approximately 3%, with comparable rates in…
View Post 5 min This content is machine translated Type 2 diabetes mellitus SGLT-2 inhibitor has cardioprotective effect in different risk groups Type 2 diabetes mellitus (T2DM) significantly increases the risk of cardiovascular complications [1]. However, SGLT-2 inhibitors may prevent cardiovascular events in addition to lowering blood glucose levels [2, 3]. For…
View Post 4 min This content is machine translated GLP-1 receptor agonists (GLP-1-RA) Type 2 diabetics benefit from dulaglutide in several ways The ADA/EASD guidelines recommend individualized therapy choices for type 2 diabetics. GLP-1 receptor agonists not only improve glycemic control, but also support weight loss, reduce the risk of cardiovascular disease,…
View Post 5 min This content is machine translated Corona pandemic Diabetes patients with COVID-19: current expert assessment. Poorly controlled diabetes is a risk factor for severe COVID-19 progression. Therefore, especially during the corona pandemic, the best possible blood glucose control is crucial. However, it has been shown…
